Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge 
Ford and Geely Explore Strategic Manufacturing Partnership in Europe 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine 
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns 
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Australian Scandium Project Backed by Richard Friedland Poised to Support U.S. Critical Minerals Stockpile 
Instagram Outage Disrupts Thousands of U.S. Users 
Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate 
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports 
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO 
Toyota’s Surprise CEO Change Signals Strategic Shift Amid Global Auto Turmoil 
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
CLEVELAND, Feb. 01, 2016 -- Athersys, Inc. (Nasdaq:ATHX) announced today that it will present at the 18th annual BIO CEO & Investor Conference to be held on February 8-9, 2016 in New York, NY, at The Waldorf Astoria New York.
Gil Van Bokkelen, Chairman and Chief Executive Officer, will present on Monday, February 8, 2016 at 2:00 p.m. EST in the Louis XVI Room.
The BIO CEO & Investor Conference is one of the largest investor conferences focused on established and emerging publicly-traded and select private biotech companies. Because its mission is to support industry-wide success, BIO presents a broad and unbiased view of investment opportunities and provides an annual forum for institutional investors, industry analysts, and senior biotechnology executives to shape the future investment landscape of the industry.
To listen to the live audio webcast of the presentation during the event, please visit: www.athersys.com. A replay of the webcast will be available for 90 days after the initial presentation.
About Athersys
Athersys is an international biotechnology company engaged in the discovery and development of therapeutic product candidates designed to extend and enhance the quality of human life. The Company is developing its MultiStem® cell therapy product, a patented, adult-derived "off-the-shelf" stem cell product, initially for disease indications in the cardiovascular, neurological, inflammatory and immune disease areas, and has several ongoing clinical trials evaluating this potential regenerative medicine product. Athersys has forged strategic partnerships and collaborations with leading pharmaceutical and biotechnology companies, as well as world-renowned research institutions to further develop its platform and products. More information is available at www.athersys.com.
Contact: William (B.J.) Lehmann, J.D. President and Chief Operating Officer Tel: (216) 431-9900 [email protected]
